Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Oncothyreon Inc. Stories

2011-11-01 07:00:00

SEATTLE, WA, Nov. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its third quarter 2011 financial results and provide a review of its pipeline of products in development on Tuesday, November 8, 2011 at 4:30 p.m. Eastern Standard Time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be...

2011-10-20 07:00:00

SEATTLE, WA, Oct. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced it has initiated the Phase 2 portion of  its ongoing Phase 1/2 trial of PX-866 in combination with the chemotherapeutic agent docetaxel (Taxotere(®))( )following successful completion of the Phase 1 dose escalation portion of the study. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important...

2011-10-17 11:40:00

SEATTLE, Oct. 17, 2011 /PRNewswire/ - Christopher Henney, Chairman of the Board of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals (Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame - special recognition of outstanding individual contributions award at the annual Biotech CEO Meeting at Laguna Beach. Henney, the co founder of Immunex, ICOS and Dendreon corporations was recognized for his...

2011-10-17 07:00:00

SEATTLE, WA, Oct. 17, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the BioCentury NewsMakers in the Biotech Industry Conference in New York on Friday, October 21, 2011 at 8:30 a.m. Eastern time. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is a biotechnology company...

2011-09-12 07:05:00

SEATTLE, WA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The open label Phase 2 trial is being conducted by the NCIC Clinical Trials Group...

2011-09-12 07:00:00

SEATTLE, WA and LA JOLLA, CA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) and Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that they have entered into an exclusive licensing agreement for sabutoclax and related compounds. Sabutoclax is a pan-inhibitor of the Bcl-2 family of anti-apoptotic proteins currently in pre-clinical development. Financial terms of the agreement were not disclosed. "Overexpression of one or more members of the...

2011-08-09 07:00:00

SEATTLE, WA, Aug. 9, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Julie Eastland, Chief Financial Officer and Vice President, Corporate Development, will present at the Wedbush Securities 2011 Life Sciences Management Access Conference in New York on Tuesday, August 16, 2011, at 11:10 a.m. Eastern Time. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events"...

2011-08-08 15:02:00

Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, Aug. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the second quarter ending June 30, 2011. Net loss from operations increased to $5.8 million in the second quarter of 2011 from $4.7 million in the second quarter of 2010, and to $11.7 million for the six months ended June 30, 2011 compared to $10.2 million for the comparable period in 2010. This increase in net loss from...

2011-08-01 07:00:00

SEATTLE, WA, Aug. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its second quarter 2011 financial results and provide a review of its pipeline of products in development on Monday, August 8, 2011 at 4:30 p.m. Eastern time. To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the...

2011-05-31 07:00:00

SEATTLE, May 31, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Jefferies 2011 Global Healthcare Conference in New York on Monday, June 6, 2011, at 8:30 a.m. Eastern Time. A live and archived webcast of Dr. Kirkman's presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon Oncothyreon is...